Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine

Publikation: Forskning - peer reviewTidsskriftartikel

DOI

  • Robin Christensen
  • Berit L Heitmann
  • Karina Winther Andersen
  • Ole Haagen Nielsen
  • Signe Bek Sørensen
  • Mohamad Jawhara
  • Anette Bygum
  • Lone Hvid
  • Jakob Grauslund
  • Jimmi Wied
  • Henning Glerup
  • Ulrich Fredberg
  • Jan Alexander Villadsen
  • Søren Geill Kjær
  • Jan Fallingborg
  • Seyed A G R Moghadd
  • Torben Knudsen
  • Jacob Brodersen
  • Jesper Frøjk
  • Jens Frederik Dahlerup
  • Anders Bo Bojesen
  • Grith Lykke Sorensen
  • Steffen Thiel
  • Nils J Færgeman
  • Ivan Brandslund
  • Tue Bjerg Bennike
  • Allan Stensballe
  • Erik Berg Schmidt
  • Andre Franke
  • David Ellinghaus
  • Philip Rosenstiel
  • Jeroen Raes
  • Mette Boye
  • Lars Werner
  • Charlotte Lindgaard Nielsen
  • Heidi Lausten Munk
  • Anders Bathum Nexøe
  • Torkell Ellingsen
  • Uffe Holmskov
  • Jens Kjeldsen
  • Vibeke Andersen
Vis graf over relationer

INTRODUCTION: Chronic inflammatory diseases (CIDs) are frequently treated with biological medications, specifically tumour necrosis factor inhibitors (TNFi)). These medications inhibit the pro-inflammatory molecule TNF alpha, which has been strongly implicated in the aetiology of these diseases. Up to one-third of patients do not, however, respond to biologics, and lifestyle factors are assumed to affect treatment outcomes. Little is known about the effects of dietary lifestyle as a prognostic factor that may enable personalised medicine. The primary outcome of this multidisciplinary collaborative study will be to identify dietary lifestyle factors that support optimal treatment outcomes.

METHODS AND ANALYSIS: This prospective cohort study will enrol 320 patients with CID who are prescribed a TNFi between June 2017 and March 2019. Included among the patients with CID will be patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis), rheumatic disorders (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin diseases (psoriasis, hidradenitis suppurativa) and non-infectious uveitis. At baseline (pretreatment), patient characteristics will be assessed using patient-reported outcome measures, clinical assessments of disease activity, quality of life and lifestyle, in addition to registry data on comorbidity and concomitant medication(s). In accordance with current Danish standards, follow-up will be conducted 14-16 weeks after treatment initiation. For each disease, evaluation of successful treatment response will be based on established primary and secondary endpoints, including disease-specific core outcome sets. The major outcome of the analyses will be to detect variability in treatment effectiveness between patients with different lifestyle characteristics.

ETHICS AND DISSEMINATION: The principle goal of this project is to improve the quality of life of patients suffering from CID by providing evidence to support dietary and other lifestyle recommendations that may improve clinical outcomes. The study is approved by the Ethics Committee (S-20160124) and the Danish Data Protecting Agency (2008-58-035). Study findings will be disseminated through peer-reviewed journals, patient associations and presentations at international conferences.

TRIAL REGISTRATION NUMBER: NCT03173144; Pre-results.

OriginalsprogEngelsk
TidsskriftBMJ Paediatrics Open
Vol/bind8
Tidsskriftsnummer2
Sider (fra-til)e018166
ISSN2044-6055
DOI
StatusUdgivet - 8 feb. 2018

ID: 53653067